{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076091","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2026-06-22T12:01:50+00:00","discovered_at":"2026-06-22T12:05:00.230815+00:00","generated_at":"2026-06-22T12:06:20.129943+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Definium Therapeutics reports positive Phase 3 results for DT120 ODT in major depressive disorder","bullets":["Study met primary endpoint with 8.1-point MADRS placebo-adjusted improvement at Week 6 (p<0.0001)","7.3-point MADRS placebo-adjusted improvement at Week 12 (p<0.0001), showing durability","DT120 ODT was generally well tolerated; no serious adverse events or suicidality signal","Company to host webcast at 8:00 a.m. EDT on June 22, 2026 to discuss results"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076091","json":"https://secwatch.observer/filing/0001104659-26-076091.json","markdown":"https://secwatch.observer/filing/0001104659-26-076091.md","text":"https://secwatch.observer/filing/0001104659-26-076091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000110465926076091/0001104659-26-076091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000110465926076091/tm2618434d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:06:20.129943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}